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Abstract
Background: A pathogenic hallmark of rheumatoid arthritis (RA) is persistent inflammatory responses in target tissues and
organs. Immune responses mediated by T cells and autoantibodies are known to play pivotal roles. A possible interpretation
for this observation is a loss of negative regulation of autoimmune responses. Here we sought to investigate whether B7-
H4, a cell surface inhibitory molecule of the B7-CD28 signaling pathway, may play a role in the pathogenesis of RA.
Methods and Findings: In a cross-sectional study of a clinical convenience sample using monoclonal antibodies against
human B7-H4 molecules, we detected high levels of the soluble form of B7-H4 (sH4) in the sera of 65% of patients with RA
(n=68) versus only 13% of healthy donors (n=24). Elevated sH4 was associated with an increased disease severity score
(DAS28) in a cross-sectional analysis. In a mouse model of RA, transgenic expression of sH4 or genetic deletion of B7-H4
accelerated the progression of collagen-induced arthritis, accompanied by enhanced T and B cell–mediated autoimmune
responses as well as increased activity of neutrophils. Expression in vivo of an agonist, a B7-H4-immunoglobulin Fc fusion
protein, profoundly suppressed disease progression in the mouse model.
Conclusions: Our findings in mice indicate that sH4 acts as a decoy molecule to block the inhibitory functions of cell-surface
B7-H4, leading to exacerbation of collagen-induced arthritis. If the preliminary correlation between sH4 levels and disease
activity in patients with RA can be confirmed to reflect a similar mechanism, these findings suggest a novel target for
treatment approaches.
Please see later in the article for the Editors’ Summary.
Citation: Azuma T, Zhu G, Xu H, Rietz AC, Drake CG, et al. (2009) Potential Role of Decoy B7-H4 in the Pathogenesis of Rheumatoid Arthritis: A Mouse Model
Informed by Clinical Data. PLoS Med 6(10): e1000166. doi:10.1371/journal.pmed.1000166
Academic Editor: Yong-Jun Liu, The University of Texas M.D. Anderson Cancer Center, United States of America
Received July 25, 2008; Accepted September 11, 2009; Published October 20, 2009
Copyright:  2009 Azuma et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was partially sponsored by US National Institutes of Health grant CA98731. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: ANA, anti-nuclear antibody; ANC, absolute neutrophil count; B7-H4, B7 homolog 4; B7-H4Ig, B7-H4-immunoglobulin Fc fusion protein; CIA,
collagen-induced arthritis; CII, type II chicken collagen; CRP, C-reactive protein; DAS, disease activity score; dsDNA, double-stranded DNA; G-CSF, granulocyte
colony stimulating factor; HD, healthy donor; HRP, horseradish peroxidase; IL, interleukin; KO, knockout; mAb, monoclonal antibody; PD-1, programmed death
one; RA, rheumatoid arthritis; sH4, soluble B7H4; TNF-a, tumor necrosis factor-alpha.
* E-mail: lchen42@jhmi.edu
PLoS Medicine | www.plosmedicine.org 1 October 2009 | Volume 6 | Issue 10 | e1000166Introduction
Chronic and persistent inflammation is a major cause for the
pathogenesis and progression of systemic autoimmune diseases
such as rheumatoid arthritis (RA). During progression of RA, the
synovial lining layer of the inflamed joints increases its thickness as
a result of synovial hyperplasia and inflammation [1,2]. The major
model for RA is collagen-induced arthritis (CIA) in which
challenge of DBA/1j mice with type II chicken collagen (CII)
induces persistent chronic inflammation in all major joints [3].
While CD4+ T cells were considered to play a central role in the
pathogenesis of RA, neutrophils may also contribute to initiation,
progression, and maintenance of RA [4–6]. For example, synovial
fluid from patients with active RA is heavily infiltrated with
neutrophils [7]. Elevated levels of granulocyte colony stimulating
factor (G-CSF), a major growth factor for neutrophils, were
detected in sera and synovial fluid from RA patients and
correlated with disease activity and severity [8]. In arthritis animal
models, depletion of Gr-1+ neutrophils resulted in a decrease of
arthritis severity [9–14]. In addition, G-CSF is also responsible for
trafficking of neutrophils into inflamed joints during progression of
CIA [15]. In experimental models, massive infiltration of Gr-1+
cells in the lesions, especially in the early phase, releases
proinflammatory cytokines including tumor necrosis factor-alpha
(TNF-a), interleukin-1 (IL-1), and IL-6, which can affect the
functions of neutrophils and other inflammatory cells [16,17]. On
the other hand, neutrophils could simply play a role as effector
cells to increase inflammation. In contrast with the CIA model,
however, neutrophil infiltration is less evident in late stages of
human RA [7].
Co-signaling molecules, including those with costimulatory and
coinhibitory functions, are important for the induction of an
effective immune response and for the prevention of unwanted
autoimmunity [18]. It has been shown that signals through the B7-
CD28 pathway are major regulators of this balance and play a
pivotal role in the regulation of autoimmunity [19,20]. Persistence
of inflammatory responses in systemic autoimmune diseases
implies either impaired coinhibitory or enhanced costimulatory
functions, leading to the loss of balance. In this regard, it is
particularly interesting that autoantibodies against B7-H1, a
primary coinhibitory molecule, are found in a significant
proportion of patients with RA and implicated in the progression
of RA symptoms [21].
Soluble forms of B7-CD28 family molecules are also implicated
in the progression of rheumatoid diseases. A recent study shows
that soluble programmed death one (PD-1) could be detected in
RA patients and the levels of soluble PD-1 are correlated with
TNF-a concentration in synovial fluid [22]. The role of these
soluble molecules in disease progression, however, remains to be
established. B7 homolog 4 (B7-H4) is a more recently identified
member of the B7 family with potent inhibitory effects in T cells
through binding to a putative receptor [23,24]. Cell surface B7-H4
is normally not detectable in normal tissues, but its surface
expression could be up-regulated on macrophages and tumor cells
by inflammatory cytokines including IL-10 and IL-6 [25]. Our
group and others reported that B7-H4 could suppress T cell
response in the presence of antigen stimulation [23,26,27]. Soluble
B7-H4 (sH4) was also detected in ovarian cancer patients as a
potential biomarker, but the mechanism of production and the
function of sH4 are unknown [28]. B7-H4-deficient mice have
been found to mount slightly enhanced T helper 1 type T cell
responses against Leishmania major infection [29]. Our study using
independently generated B7-H4-knockout (B7-H4KO) mice
demonstrated that the lack of B7-H4 led to resistance to Listeria
monocytogenes infection by lifting suppression on the growth of
neutrophil progenitors [30]. Taken together, these studies indicate
that B7-H4 is an important inhibitory molecule to keep the
inflammatory response in check.
In this study we investigated whether sH4 could be detected in a
higher quantity in the sera from RA patients than healthy donors
(HDs), and whether levels were associated with disease activity.
The results lead us to postulate that sH4 acts as a decoy to impair
endogenous B7-H4-mediated suppression of inflammatory re-
sponses. We then tested this hypothesis in a CIA mouse model.
Materials and Methods
Patients and HDs
Patients were recruited from a convenience sample enrolled
serially as they were seen in the outpatient clinic. Diagnoses of RA
[31] are based on the Criteria for Classification of Rheumatoid
Arthritis by the American Rheumatism Association. The HDs had
no history of autoimmune diseases and were recruited similarly.
The study and protocol were approved by the Internal Review
Board of the Mayo Clinic and all patients and HDs gave written
informed consent for this study. The characteristics of RA patients,
including anti-nuclear antibody (ANA), absolute neutrophil count
(ANC), C-reactive protein (CRP), and clinical treatment, are
summarized in Table S1. The disease activity score 28 (DAS28)
ranges from 0 to 10 and includes the 28 tender and swollen joint
counts, the erythrocyte sedimentation rate (Westergren, mm/h),
and the patient’s general health measured with a visual analog
scale (100 mm) [32]. DAS28.5.1 indicates that the patient has
high disease activity, DAS28 of 3.3 to 5.1 means that disease
activity is moderate, DAS of 2.7 to 3.2 is categorized as low disease
activity, and DAS,2.6 indicates remission. The DAS assessment
was done shortly prior to the blood draw (within 2 h). The drugs
for RA treatment were taken at the time of the DAS evaluation
and blood draw.
Detection of sH4 and Autoantibodies against Collagen
For detection of human sH4, specific monoclonal antibodies
(mAbs) hH4.3 (2 mg/ml) and hH4.1 (2 mg/ml) against human B7-
H4 [24] were used as capture and detection, respectively, by
sandwich ELISA. To remove rheumatoid factor, the sera were
treated with human IgG agarose (Sigma-Aldrich, St. Louis, MO)
before detection by ELISA. After this treatment, sera do not react
to human/rat IgG, indicating complete elimination of potential
cross-reactivity. For measurement of collagen-specific autoanti-
bodies, chicken collagen (1 mg/ml) was coated on the plate
overnight at 4 uC, and biotin-conjugated anti-mouse IgG, IgG1,
IgG2a, and IgG2b antibodies (BD, San Jose, CA) were used as
detection antibodies. ELISA was conducted according to the
procedures described previously [21].
For detection of mouse sH4 by sandwich ELISA, specific mAb,
clone mH4.5 [23] at 2 mg/ml, was used as capture antibody. As
detection antibody, polyclonal antibodies were prepared by
immunization of a rat with peptides encoding B7-H4 IgV
domain-KLH conjugate, as in the procedure described previously
[33]. All sera were pretreated with mouse IgG agarose (Sigma-
Aldrich) to remove rheumatoid factor before ELISA.
Western Blot
The sera were mixed with 26 sample buffer (4% SDS, 0.2%
bromophenol blue, 20% glycerol in 100 mM Tris-buffered saline)
and boiled for 5 min. The samples were electrophoresed under
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CA) and the proteins electroblotted onto Protran BA85 (What-
man, Florham Park, NJ). The Immobilon-P sheet was blocked in
5% nonfat dry milk in PBS for 1 h and incubated with the
antibody (clone hH4.1) at 4uC overnight. After repeated washing
(five times for 5 min), bound antibody was detected with
horseradish peroxidase (HRP)–labeled streptavidin (Biosource,
Camarillo, CA), incubated for 1 h, and visualized by chemilumi-
nescent substrate (Supersignal Substrate, Pierce, Rockford, IL).
Mice
Male DBA/1j mice were purchased from Jackson Laboratory
(Bar Harbor, ME). Age-matched mice, 4–10 wk old, were used for
all experiments. B7-H4KO mice were generated from 129/B6
embryo stem cells in our laboratory [30] and have been
backcrossed to B6 background for 10 generations. DBA/1j6B7-
H4KO mice were generated by backcrossing B7-H4KO mice into
DBA/1j backgrounds for eight generations. Two markers on the
upstream of B7-H4, D3mit21 (19.2 cM), and D3mit278 (33.7 cM)
and two markers on the downstream of B7-H4, D3mit318
(58.8 cM), and D3mit127 (70.3 cM) are all DBA/1 products
(unpublished data). All mice were maintained in the Animal
Facility at Johns Hopkins University under a protocol approved by
the Institutional Animal Care and Use Committee.
Antibodies and Flow Cytometry Analysis
Purified mAbs against mouse Gr-1 (RB6-8C5) and CD11b
(M1/70) were purchased from PharMingen (San Diego, CA).
Fluorescence was detected by FACScan flow cytometry and
analyzed with Cell Quest software (Becton Dickinson, Mountain
View, CA).
Induction of CIA
CIA was induced in 8- to 10-wk-old male DBA/1j mice by
intradermal tail base injection of 0.2 mg chicken collagen (Sigma-
Aldrich) in 0.05 M acetic acid, supplemented with 4.0 mg/ml
Mycobacterium tuberculosis (DIFCO, Detroit, MI) emulsified in
complete Freund adjuvant. Twenty-one days after first primary
immunization, the mice were identically boosted once. Severity of
disease was evaluated by visual inspection of the paws. Each paw
was scored for the degree of inflammation on a scale from 0 to 4
where 0, no evidence of erythema and swelling; 1, erythema and
mild swelling confined to the midfoot (tarsals) or ankle joint; 2,
erythema and mild swelling extending from ankle to the midfoot;
3, erythema and mild swelling extending from ankle to metatarsal
joints; and 4, erythema and severe swelling encompassing the
ankle, foot, and digits. Scores from all four paws were added to
give the total for each animal.
Murine B7-H4 Constructs
The B7-H4 immunoglobulin fusion (B7-H4Ig) construct was
described previously [23]. To generate plasmids of B7-H4V,
which contains only Ig V region of B7-H4, and B7-H4VC, which
have both Ig V and Ig C regions, , two flanking 59 and 39 primers
were designed with XhoI and EcoRI restriction sites, respectively
(59 primer, 59-CCGCTCGAGCCACCATGGCTTCCTTGGG-
GCAG-39;3 9 primer for B7-H4V, 59-CGGAATTCCGCTAA-
TTTATCTCTGGCATACT-39;3 9 primer for B7-H4VC, 59-C-
GGAATTCCGCTAAGAGTTCAGCAACTGCAG-39). Appro-
priate regions of cDNA were amplified using primers. PCR
product was digested with XhoI and EcoRI and ligated into
XhoI/EcoRI-digested pcDNA3.1 vectors (Invitrogen, Carlsbad,
CA).
Hydrodynamic Injection and Antibody Treatment
Mice were injected with indicated plasmid on day 21 and day
13 in the CIA model. Hydrodynamic injection was performed as
previously described [34]. Briefly, 30 mg of plasmid DNA in 3 ml
of PBS was injected into the tail vein within 10 s. Mouse survival
was 100% after injection. To delete granulocytes, mice were
injected i.p. with 0.3 mg of anti-Gr-1 mAb (clone RB6-8C5, rat
IgG2b). The controls that were used in the study were either
control polyclonal rat IgG (Sigma) or anti-human HLA-Bw6 mAb
(clone SFR8-B6, rat IgG2b) every other day.
Collagen-Specific T Cell Proliferation and Cytokine
Production
The spleen was removed on day 14 after the last immunization.
CD4+ T cells were purified by using magnetic beads (Miltenyi
Biotec, Auburn, CA). Whole splenocytes or purified CD4+ T cells
were stimulated with denatured (60uC, 30 min) CII in 96 well flat
bottom microtiter plates for 72 h, and pulsed with [
3H] thymidine
(1 mCi/well) (Amersham Pharmacia Biotech, Piscataway, NJ) for
the final 12 h. In the culture of purified CD4+ T cells, irradiated
(50 Gy) splenocytes from the syngeneic mice were added as
antigen-presenting cells. Supernatants from the cultures were
collected after 48 h and assayed for mouse IFN-c (BD) and IL-17A
(eBioscience) using the ELISA kit according to the protocols
recommended by the manufacturer.
Histological Assessments of Arthritis
CIA mice were humanely killed at day 35. The hind paws were
removed, fixed in formalin, decalcified in 10% EDTA, embedded
in paraffin, sectioned, and stained with hematoxylin and eosin.
Statistical Analysis
We performed statistical analysis with the Mann-Whitney U test
for single comparison and ANOVA followed by the Scheffe ´ test for
multiple comparisons. Correlations were performed with the
Spearman rank test. For longitudinal multiple comparisons,
repeated ANOVA followed by the Tukey-Kramer test was used.
The unpaired Student two-tailed t-test was applied for single
comparison of parametric data. Independent associations between
one dependent variable and more than two independent variables
were assessed by multiple regression analysis. Specifically, the
dependent variable, sH4 concentration, was regressed for RA, age,
and sex. In all statistical analyses, significance was accepted at
p,0.05.
Results
Increased sH4 in the Sera from Patients with RA
The characteristics of RA patients, including their age, sex,
disease duration, ANA, ANC, CRP, sH4 levels, clinical treatment,
and DAS28 score, are summarized in Table S1. Serum samples
were obtained from 68 patients with diagnosed RA (55 women
and 13 men, mean age=56 y; age range: 19–80 y) and 24 HDs
(19 women and 5 men, mean age=54 y; age range: 20–69 y) as
controls. The treatment history of patients before and after
admission was listed in Table S1.
To detect sH4, sera from individual patients with a diagnosis of
RA were analyzed by ELISA using two specific mAb binding to
different epitopes on human B7-H4. In this assay, 65% (44 out of
68) samples from patients with RA were above background for
sH4 and therefore considered positive. Evaluation of sH4 in HDs
showed only 13% (3 out of 24) to be positive (p,0.001) (Figure 1A).
The levels of sH4 were also significantly higher in RA patients
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PLoS Medicine | www.plosmedicine.org 3 October 2009 | Volume 6 | Issue 10 | e1000166Figure 1. Detection of sH4 in sera from RA patients. (A) The concentration of the sH4 in HDs and in the patients diagnosed with RA. Sera from
68 RA patients and 24 HDs were diluted 1:10 in PBS and tested by ELISA as described in Materials and Methods. The data were analyzed by the Mann-
Whitney U test followed by a multiple regression analysis (p,0.01). (B) The sH4 in sera of RA patients was detected by Western blotting using HRP-
labeled anti-human B7-H4 mAb (clone hH4.3). A 50 kDa sH4 band was detected in the sera of three patients with RA but not in the sera from three
HDs. (C) The correlation of serum sH4 levels and disease severity in the patients with RA. Patients with RA were classified into four severity groups
based on DAS28 score described in the Materials and Methods. The concentration of sH4 in the serum of each patient was determined by ELISA as
described above. Statistical analysis was performed by ANOVA method followed by the Scheffe ´ test. The bars represent the mean concentration of
sH4 in all donors of each group (ng/ml).
doi:10.1371/journal.pmed.1000166.g001
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significantly higher than those of the HDs (,5 ng/ml) (Figure 1A).
We subsequently performed Western blot analysis to validate
the presence of sH4 in sera from three patients with RA. Using
specific mAb against B7-H4, the sera from three patients (numbers
27, 38, and 59, see Table S1), who had the highest level of sH4 on
ELISA, showed a single 50 kDa band. This matches the size of the
predicted extracellular domain of human B7-H4 [23]. In contrast,
no band was observed in sera from three HDs, who also had the
highest level of sH4 on ELISA (Figure 1A and 1B). Our data
support the presence of sH4 in the sera of patients with RA.
Increased Serum sH4 Is Associated with Active Disease
Status
We next determined whether elevated sH4 is associated with the
activity of RA. Based on disease activity categorized by the DAS28
score system, 68 patients with RA were classified into four groups
with remission patients in the lowest disease activity and with low,
moderate, and high activity as described in Materials and
Methods. The mean concentration of sH4 in the high activity
group (321.6 ng/ml) was significantly higher than those of the
remission group (18.93 ng/ml) or low activity group 1 (27.17 ng/
ml). However, there was no significant difference among
remission, low, and moderate activity group by Scheffe ´ test
(Figure 1C). In addition, the presence of sH4 in these patients
is also significantly associated with elevated CRP levels in the sera,
a nonspecific surrogate marker for ongoing inflammation
(Figure S1).
sH4 Exacerbates CIA in a Mouse Model
To recapitulate and explore the possible role of sH4 in the
pathogenesis of RA, we employed a mouse model of CIA. CIA is a
well-characterized mouse model for human arthritis, in which
injection of CII into male DBA/1j mice induces swelling and
progressive inflammation in large and small diarthrodial joints and
leads to arthritis. We first tested whether sH4 is present in this
model. To do so, we established a specific ELISA using two mAbs
against distinct epitopes of murine B7-H4 (see Materials and
Methods). The sera from the mice after CII immunization were
drawn from the tail vein, absorbed by mouse IgG–conjugated
agarose to remove potential rheumatoid factor, and subjected to
ELISA analysis. A significant increase of sH4 could be detected up
to 300 ng/ml 1 d after immunization in the sera of all mice. This
expression, however, was transient and became non-detectable at
Day 5 (Figure S2) and did not reappear throughout the entire
course of disease progression. Immunization of mice with CFA
alone or injection of Con A or LPS, however, did not induce this
transient elevation of sH4 in blood (unpublished data), suggesting
that sH4 is not a general marker for inflammation. Therefore, we
could not establish a correlation between endogenous sH4 and
CIA progression in this model.
As an alternative approach to determine the role of sH4, we
sought to express sH4 in vivo. To do so, we constructed an
expression vector, B7-H4VC, in which the truncated gene
encoding both IgV and IgC domains was placed under the
control of the cytomegalovirus (CMV) immediate early promoter.
We also prepared another vector, B7-H4V, containing only IgV
domain of B7-H4 (Figure 2A). After expression, these truncated
proteins/polypeptides were expected to compete with endogenous
B7-H4 on the cell surface for binding its putative receptor.
Parental vector or the vector with the gene encoding flag peptide
was included as a control. By a hydrodynamic expression
procedure [34], injection of these plasmids led to expression of
sH4 up to 2 mg/ml in the sera, based on specific capture sandwich
ELISA using two anti-mouse B7-H4 mAbs. The levels of sH4
declined rapidly and become non-detectable by day 7 after
injection (Figure S3).
Immunization of DBA/1j mice with CII led to appearance of
arthritic symptoms at 25 d. After hydrodynamic injection with
control vector, and 80% of mice developed disease on day 49, a
result similar to CIA mice without plasmid injection (unpublished
data), indicating hydrodynamic injection itself does not signifi-
cantly change the course of CIA progression. Injection of B7-
H4VC vector, however, led to earlier development of disease (18 d
after) and 100% of mice developed arthritis at around Day 35.
Similar results were also seen in the mice injected with B7-H4V
(Figure 2B, 2C). Treatment by either B7-H4V or B7-H4VC also
significantly increased severity of arthritis as indicated by increased
clinical score (Figure 2C), increased swelling of footpad (Figure
S4), and increased infiltration of inflammatory cells in joints as
shown in histopathology analysis (Figure S5). Additional control
vector containing genes encoding flag peptide or B7-H4-flag fusion
protein produced similar results (Figure S6). Our results suggest
that decoy B7-H4 could exacerbate CIA and facilitate disease
progression.
Assessment of cellular and humoral immune responses revealed
that increased incidence and severity of arthritis was accompanied
with elevated total IgG autoantibodies (Figure 2D) as well as other
subtypes, including IgG1, IgG2a, and IgG2b against CII at day 30
after immunization and B7-H4VC or B7-H4V treatment (Figure
S7). Stimulation of total spleen cells (Figure 2E) or purified CD4+
T cells (Figure S8) from mice, which were treated with B7-H4VC
or B7-H4V, by CII also induced much higher levels of
proliferation in comparison with mice treated with control vector.
Importantly, IFN-c and IL-17, two major cytokines responsible for
CIA progression, also increased significantly in the cultures
(Figure 2F). Taken together, our data demonstrate that sH4
enhances autoimmune responses against CII and exacerbates
autoimmune CIA.
B7-H4-Deficient Mice Develop Exacerbated CIA
If B7-H4VC and B7-H4V act as decoy molecules to block the
effect of endogenous B7-H4 on the cell surface, a prediction is that
a similar exacerbating effect should also be observed in the mice
lacking endogenous B7-H4. To validate this finding, we
backcrossed B7-H4-deficient (KO) mice [30] to DBA/1j mice
for eight generations. B7-H4-deficient DBA/1j mice develop
normally and do not have obvious abnormalities in gross
appearance and immune system development. These mice,
however, developed much more severe CIA after CII immuniza-
tion, showing higher arthritis incidence (Figure 3A) and clinical
scores (Figure 3B) than B7-H4+/+ littermates. In addition,
autoimmune responses, including T cell responses and autoanti-
bodies to CII, were also significantly increased above control
(unpublished data). These results are similar to those from B7-
H4VC- or B7-H4V-treated mice. Therefore, our data further
support the concept that sH4 functions as a decoy molecule to
block endogenous B7-H4, leading to increased autoimmune
responses and exacerbated CIA.
Neutrophils in sH4-Mediated Enhancement of
Autoimmunity and CIA Exacerbation
Our recent study indicates that B7-H4KO mice have an
accelerated response of neutrophils to infection and inflammation
partially due to B7-H4-mediated growth inhibition of bone
marrow–derived neutrophil progenitors [30]. These findings
implicate a role of neutrophils in sH4-mediated disease exacerba-
tion. We quantified the Gr-1+ Mac-1+ neutrophils in peripheral
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PLoS Medicine | www.plosmedicine.org 5 October 2009 | Volume 6 | Issue 10 | e1000166Figure 2. sH4 exacerbates disease in CIA model. (A) Schematic representation of the full length murine B7-H4, B7-H4V, B7-H4VC, and B7-H4Ig
fragments, which were inserted into pcDNA plasmid. IgV, immunoglobulin V-like region; IgC, immunoglobulin C-like region; TM, transmembrane
region; CT, cytoplasmic tail. Effect of decoy B7-H4 in incidence (B) and (C) clinical score of CIA. Mice were immunized with CII in complete Freund’s
adjuvant (CFA) on day 0 and day 21. The incidence and clinical score were recorded daily based on the standard described in Materials and Methods.
Three groups of mice were injected with the indicated plasmids on day 21 and day 20. Each point represents results from pool of ten mice and
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immunization. Gr-1+ Mac-1+ cells were more frequent in B7-
H4 KO mice (42.4%) than in littermate controls (21.2%)
(Figure 4A). Similar results were also observed after treatment
with the plasmids encoding B7-H4VC or B7-H4V (unpublished
data). Because Gr-1+ cell increases precede adaptive autoimmu-
nity, which appears at least 1 wk after exposure to CII
immunization, it is thus possible that increased Gr-1+ cells may
regulate subsequent development of T and B cell–mediated
autoimmune response.
We next depleted Gr-1+ cells by anti-Gr-1 antibody to
determine their role in CIA. Because symptoms and pathology
of arthritis appear around 25–30 d after first CII immunization,
CIA could be divided into induction phase (before appearance of
symptoms) and effector phase (after appearance of symptoms). We
first examined the effect of neutrophil depletion in sH4-mediated
exacerbation of CIA. CIA mice were treated with B7-H4VC
vectors and inoculated with anti-Gr-1 depleting antibody every
other day from day 21 to 14. By this method, .90% of Gr-1+
cells were depleted throughout the treatment period based on flow
cytometry analysis using anti-Gr1/Mac-1 mAb (unpublished data).
Increased CIA clinical score induced by sH4 was eliminated by
this treatment (B7-H4VC+Ctl IgG group versus B7-H4VC+anti-
Gr-1 mAb group) (Figure 4B). Our result supports the hypothesis
that neutrophils are required for sH4-mediated exacerbation of
CIA. Furthermore, in the condition of anti-Gr-1 depletion, B7-
H4VC treatment did not have a significant effect in exacerbation
of CIA (Figure 4B). Interestingly, anti-Gr1 mAb did not suppress
CIA induced by CII without sH4, suggesting that the neutrophil-
mediated mechanism is unique for sH4. Taken together, our data
indicate the sH4-mediated exacerbation of CIA is dependent on
Gr-1+ cells.
We also depleted Gr-1+ cells in the effector phase of CIA to
determine the role of Gr-1+ cells. In contrast to the treatment in
the induction phase, depletion of Gr-1+ cells in the effector phase
had only a marginal effect in B7-H4VC plasmid-induced CIA
exacerbation (Figure S9). Because this treatment also inhibited
CIA severity without B7-H4VC treatment (CtlV+Clt IgG versus
CtlV+anti-Gr1 mAb), this marginal effect may not be sH4
dependent. In addition, even when Gr-1+ cells were depleted,
B7-H4VC plasmid treatment could still induce exacerbation of
CIA (CtlV+anti-Gr1 mAb versus B7-H4VC+anti-Gr1 mAb).
These findings indicate that Gr-1+ cells have a minimal role in
sH4-mediated exacerbation of CIA, which is in contrast to their
role in the induction phase, in which depletion of Gr-1+ cells
eliminated the effect of sH4 (Figure 4B).
To confirm that the depletion of Gr-1+ cells affects subsequent
generation of adaptive autoimmune responses, we evaluated the
anti-collagen antibody (Figure 4C) and T cell proliferation to
collagen (Figure 4D) in the sH4-excerbated CIA model after
depletion of Gr-1+ cells. In CIA mice treated by B7-H4VC
plasmid, the depletion of Gr-1+ cells completely inhibited the
production of sH4-mediated increases of autoantibodies and T cell
proliferation to collagen.
Suppression of CIA by Agonist B7-H4
While our data show that sH4 in mouse models promotes CIA,
these data also support the view that endogenous B7-H4 is a
checkpoint molecule in suppressing autoimmune responses.
Therefore, a potential approach to suppressing autoimmune
diseases is to increase the expression of B7-H4 in the form of
agonist in order to engage its putative receptor. To do so, we
constructed B7-H4Ig fusion protein in which the B7-H4
extracellular domain was fused to mouse IgG2a Fc portion as
described previously [23,35]. The Fc portion of B7-H4Ig could
bind Fc receptor–positive cells to facilitate the agonist effect in
vivo. In the control vector, signal sequence of B7-H4 was fused to
murine IgG2a Fc portion. B7-H4Ig and the control vector were
transfected into 293 T cells and the same level of production of Fc
was confirmed with two plasmids (unpublished data).
The effect of B7-H4Ig on preventing the progression of CIA was
first tested. The plasmids were injected hydrodynamically 1 d
before CII immunization and the same treatment repeated 1 d
before CII challenge at day 21. In comparison with the control
vector, B7-H4Ig plasmid treatment significantly delayed the onset
of CIA and decreased the incidence and clinical score of arthritis
(Figure 5A, 5B). Furthermore, B7-H4Ig plasmid treatment
suppressed the production of total IgG (Figure 5C) and IgG1,
IgG2a, and IgG2b autoantibodies to CII (Figure S7). Finally,
proliferation of splenocytes (Figure 5D) and CD4+ T cells (Figure
S8), as well as IFN-c and IL-17 production in response to CII,
were also significantly suppressed upon B7-H4Ig treatment
(Figure 5E). The treatment also significantly suppressed joint
swelling (Figure S4) and inhibited infiltration of inflammatory cells
(Figure S5), including Gr-1+ cells and lymphocytes (unpublished
data). Collectively, our results support that B7-H4Ig works as an
agonist for its putative receptor to suppress both humoral and
cellular autoimmunity. In addition, this method is also effective in
suppressing progression of CIA.
We next evaluated whether B7-H4Ig could be applied to treat
established CIA. Mice were immunized with CII on day 0 and day
21. When the mice had a clinical score of 2, which happened
between 20–36 d after initial CII immunization, they were
injected with B7-H4Ig or control plasmids and the same
treatments were repeated once 2 wk later. As shown in
Figure 5F, B7-H4Ig plasmid treatment significantly suppressed
expressed as means 6 95% confidence interval. Data represent three independent experiments. Statistical analysis was performed by repeated
ANOVA method (p,0.0001). The following Tukey-Kramer test showed significant differences at each points after day 28 between the control group
and other two groups (p,0.01). (D) Effect of decoy B7-H4 in the generation of autoantibodies against CII in CIA sera. CIA mice were treated with
indicated plasmids and sera were sampled at day 30 after collagen immunization. Serum levels of IgG against CII were determined by specific ELISA
as described Materials and Methods. Each group represents results from a pool of five mice. The top and bottom of each rectangular box denotes the
75th and 25th percentiles, respectively, with the median shown inside the box. Error bars extending from each box represent the maximum and
minimum. Data represent three independent experiments. Statistical analysis was performed by ANOVA method followed by the Scheffe ´ test. (E)
Effect of decoy B7-H4 in the proliferation of T cells reactive to collagen in CIA mice. CIA mice were first treated with indicated plasmids in vivo as
indicated in (B). Whole splenocytes from the mice at day 30 after collagen immunization were cultured in the presence of the indicated
concentrations of CII for 72 h. The cultures were pulsed with
3HTdR 18 h before harvest, and cpm were determined by a scintillation counter. Each
point represents results from three wells and data represent two independent experiments and expressed as means695% confidence interval. (F)
Effect of decoy B7-H4 in the production of cytokines from splenocytes reactive to CII in CIA mice. Supernatants in splenocyte cultures as described in
(E) at 72 h were collected and assessed for IFN-c and IL-17 by ELISA. Each group represents results from three wells and data represent three
independent experiments. The top and bottom of each rectangular box denote the 75th and 25th percentiles, respectively, with the median shown
inside the box. Error bars extending from each box represent the maximum and minimum. Statistical analysis was performed by ANOVA followed by
the Scheffe ´ test.
doi:10.1371/journal.pmed.1000166.g002
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severity of CIA was significantly suppressed up to 40 d after initial
treatment.
Discussion
sH4 is found in sera of approximately two-thirds of the RA
patients we sampled, and the concentration of sH4 appears to
correlate with activity of disease. In the CIA mouse model, we
found evidence that sH4 acts as a decoy molecule to block
suppressive functions of endogenous B7-H4, leading to enhanced
autoimmune responses and exacerbation of CIA. We also
demonstrated that agonist B7-H4Ig is a potent inhibitor of CIA
progression. Therefore, our findings may have implications for
prediction of RA disease progression and potential novel
therapeutic approaches to RA.
sH4 is approximately 50 kDa by Western blot analysis
(Figure 1B), which is larger than the extracellular domain of
monomeric B7-H4 molecule in denatured conditions; the
predicted size of B7-H4 is 26 kDa. This size discrepancy could
be due to glycosylation, since B7-H4 has several potential
glycosylation sites. This is consistent with a recent report showing
Figure 3. B7-H4-deficient mice develop more severe CIA. (A) CIA incidence and (B) clinical score in the littermate (WT) or B7-H4 knockout (B7-
H4KO) mice. The indicated mice were immunized with CII in CFA on day 0 and day 21. Each point represents results from a pool of ten mice. Data
represent two independent experiments and expressed as means 6 95% confidence interval. Statistical analysis was performed by repeated ANOVA
method (p,0.0001). The following Tukey-Kramer test showed significant difference at each points after day 28 (p,0.01).
doi:10.1371/journal.pmed.1000166.g003
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PLoS Medicine | www.plosmedicine.org 8 October 2009 | Volume 6 | Issue 10 | e1000166Figure 4. Gr-1+ cells are required for sH4-mediated exacerbation of CIA. (A) Flow cytometry analysis of peripheral blood from the B7-H4KO
or littermates on Day 2 after being immunized with collagen in CFA. The percentages of Gr-1+ Mac-1+ cells are shown and the results are presented
as means6standard deviation (n=5). Data are representative of two independent experiments. (B) Depletion of Gr-1+ neutrophil ameliorates sH4-
induced exacerbation of CIA. Mice were treated with either control (ctlV) or B7-H4VC plasmids (B7-H4VC) at day 21 and 14 of collagen immunization
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of sH4, however, remains unknown. One possibility is enzymatic
cleavage of the entire extracellular portion of B7-H4. In our
preliminary study, 293 T cells transfected with full-length B7-H4
cDNA release sH4 into culture supernatants, and this secretion
could be inhibited by incubation with various proteases inhibitors
(Azuma et al., unpublished data). Our results also indicate sH4
containing only the IgV portion is sufficient to exacerbate
autoimmune diseases, because B7-H4V has similar effects to B7-
H4VC. This is consistent with our previous findings that the
binding site for its putative receptor is located in the IgV domain
based on a computer-generated model [23]. B7-H4 was suggested
to be a glycosylphosphatidylinositol (GPI)-anchoring protein [26],
which could become soluble by detaching its anchoring [36].
However, a recent study shows that B7-H4 is a transmembrane
protein [37]. Another possibility is that sH4 is made from an
alternatively spliced form. Several molecules in the immunoglob-
ulin superfamily have been shown to display soluble forms
[22,38–40] and these soluble molecules, including CD80, CD86,
and PD-1, are made by splicing variants [22,38,39]. Therefore,
this possibility could not be excluded at the present time.
We found elevated sH4 in 65% of RA patients in our study
population. These figures, however, might represent an underes-
timation of the true proportions of patients with sH4 elevations.
Each patient was sampled only once, at their clinic visit, and the
concentration of serum sH4 may vary during disease progression.
In addition, all patients were already under treatment with various
regimens (Table S1) and such treatment may affect the production
of sH4. A kinetic study with multiple blood draws in newly
diagnosed patients in a prospective setting will be ideal to address
these issues. Nevertheless, our data show that patients with highly
active RA have significantly higher levels of sH4 than the patients
in remission or with low disease activity. It appears to be a trend
that a higher level of sH4 is associated with increased RA activity.
However, sH4 in the patients with moderate disease activity was
not significantly different from the patients in remission
(Figure 1C). This observation may need to be further tested by
increasing the number of patients in each study group to increase
statistical power. While our data suggest a correlation of elevated
sH4 in sera to disease activity and severity, it is difficult to
determine the role of sH4 in the pathogenesis of human RA. To
help address this issue, we applied mouse CIA models, a well
characterized mouse model for human RA, to further address if
sH4 could promote disease activity. Using a hydrodynamic
injection method to express B7-H4 plasmid in vivo, we
demonstrated that expression of sH4 promotes autoimmune
responses, leading to progression of CIA, and similar results are
also observed in B7-H4–deficient mice. In contrast, introduction of
the plasmid encoding B7-H4Ig could prevent disease induction of
CIA. More strikingly, treatment of ongoing autoimmune disease
by B7-H4Ig was also effective. While our results in the mouse CIA
model suggest a role of B7-H4 in pathogenesis of CIA, one should
be cautious because the CIA model does not mimic human RA in
all aspects, and it remains to be tested whether sH4 participates in
the development of human RA. Elevation of sH4 may also serve as
a disease severity marker because a significant fraction of RA
patients who have elevated sH4 had more severe RA than those
without sH4 in their sera. To establish this as a biomarker,
however, would require further studies including more patients
and preferably at their primary visit.
The effect of endogenous B7-H4 in the inhibition of T and B
cell–mediated autoimmune responses in the CIA mouse model is
evident as shown in increased T and B cell responses by B7-H4
blocking. This is shown in vivo by transgenic expression of sH4 or
B7-H4 genetic knockout. In addition, expression of agonist B7-
H4Ig fusion protein significantly inhibits T cell and autoantibody-
mediated responses. Consistent with previously published obser-
vations from different laboratories, our observation thus supports a
critical role of B7-H4 in the inhibition of adaptive immunity,
leading to suppression of autoimmune diseases in the CIA model.
It has been shown that B7-H4 executes its effect by inhibiting cell
cycle progression of T cells in the presence of antigen stimulation
[23] while a direct effect of B7-H4 on B cells has not been
documented. In addition to T and B cell immunity, our results also
implicate a role of Gr-1+ cells in sH4-induced exacerbation of
CIA. First, neutrophil numbers increase rapidly in peripheral
blood after sH4 exposure in CIA (Figure 4A and Azuma et al.,
unpublished observation). Second, infiltration of Gr-1+ cells
increases in various disease organs (Figure S5 and Azuma et al.,
unpublished observation). Finally, depletion of Gr-1+ cells
eliminates the effect of sH4. Our experiments indicate that Gr-
1+ cells contribute to the induction phase of sH4-mediated
enhancement of autoimmunity and disease exacerbation while its
role in the effector phase is minimal (Figures 4B and S9). While
Gr-1+ cells are largely neutrophils, they may also contain a small
number of plasmatoid dendritic cells [41]. It is tempting to
speculate that secretion of sH4 in RA first enhances innate
immunity by stimulation of Gr-1+ cells and subsequently facilitates
adaptive autoimmunity. It is unclear at the present time how Gr-
1+ cells enhance autoimmune immune responses, but various
studies indicate that Gr-1+ cells may do so by inducing maturation
of dendritic cells [42]. Because sH4 could be present in these
patients for a long period of time, our findings suggest a possible
mechanism for persistent inflammation. In addition to their
antimicrobial effect, Gr-1+ neutrophils have been implicated in
autoimmune disease and chronic inflammation [4,5,6]. In this
context, neutrophil infiltration is considered to play an important
role in arthritis pathology in a number of animal models including
K/BxN serum-induced arthritis, anti-type II collagen antibody
induced arthritis, Lyme arthritis, adjuvant arthritis, streptococcal
to induce CIA. To deplete Gr-1+ cells, mice were injected i.p. with 0.3 mg of anti-Gr-1 mAb (clone RB6-8C5) or control rat IgG every other day starting
at day 21 of CIA induction and stopping at day 14. Each point represents results from a pool of ten mice and the bars are means 6 95% confidence
interval. Data are representative of two independent experiments. Statistical analysis was performed by repeated ANOVA method (p,0.0001). The
following Tukey-Kramer test showed significant difference at each point after Day 28 between the B7-H4VC+ Ctl IgG group and other three groups
(p,0.01). (C) Depletion of Gr-1+ cells inhibited sH4-mediated production of autoantibodies to collagen. CIA mice were treated with indicated
plasmids and anti-Gr-1 antibody as described in (B). Sera were sampled on day 30 after collagen immunization. Serum anti-collagen IgG level was
determined by specific ELISA as described in Materials and Methods. Each group represents results from a pool of five mice. The top and bottom of
each rectangular box denote the 75th and 25th percentiles, respectively, with the median shown inside the box. Error bars extending from each box
represent the maximum and minimum. Data are representative of two independent experiments. Statistical analysis was performed by ANOVA
method followed by the Scheffe ´ test. (D) Depletion of Gr-1+ cells inhibited sH4-mediated proliferation of splenocytes to CII. CIA mice were treated
with indicated plasmids and anti-Gr-1 antibody as described in (B). Whole splenocytes from the mice at day 30 after collagen immunization were
cultured in the presence of the indicated concentrations of CII for 72 h. The cultures were pulsed with
3HTdR 18 h before harvest and cpm were
counted by a scintillation counter. Each point represents results from three wells and data represent five independent experiments and are expressed
as means 6 95% confidence interval.
doi:10.1371/journal.pmed.1000166.g004
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PLoS Medicine | www.plosmedicine.org 10 October 2009 | Volume 6 | Issue 10 | e1000166Figure 5. B7-H4Ig fusion protein suppresses autoimmune responses and development of CIA. (A) Inhibition of CIA incidence and (B)
clinical score by treatment with the plasmid containing the gene encoding B7-H4Ig fusion protein. Mice in groups of ten were immunized with CII in
CFA on day 0 and day 21 and observed daily. The incidence and clinical score were recorded based on the standard method described in Materials
and Methods. Indicated plasmids were injected on day 21 and day 20 of CIA induction. Data are representative of three independent experiments
and the data of clinical scores are expressed as means 6 95% confidence interval. Statistical analysis was performed by repeated ANOVA method
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neutrophil depletion or neutrophil-derived mediators could
ameliorate the severity of arthritis. Neutrophils can synthesize a
variety of cytokines and chemokines [16,17]. Chemokines released
by Gr-1+ cells could also amplify inflammation by recruiting more
Gr-1+ cells and other inflammatory cells into the inflammatory site
[45–47]. Although our results suggest a potential role of Gr-1+
cells on the induction of autoimmunity, depletion of Gr-1+ cells
does not eliminate the induction of CIA by antigen+adjuvant
(Figure 4B). Therefore, a neutrophil-dependent mechanism may
operate only in the presence of sH4.
Increased neutrophils in peripheral blood have been found in
RA patients and this elevation was shown to be associated with
more severe disease [48], suggesting a potential role of neutrophils
in the exacerbation of RA. Neutrophils are mostly found in RA
patients’ synovial fluid of the involved joints, which is different
from the CIA model in which infiltration of neutrophils in the joint
lesion is evident. While it is impossible at the present time to
establish a causal relationship among increased sH4/neutrophils
and severe RA diseases clinically, our findings suggest this
possibility and encourage further study to elucidate this issue.
In summary, our findings in the CIA mouse model support a
critical role for B7-H4 as a checkpoint molecule and provide a
possible explanation for the pathogenesis and progression in a
significant fraction of patients with RA. Production of decoy B7-H4
in these patients may facilitate disease progression by enhancing
innate immune responses, leading to amplified adaptive autoim-
mune responses against self antigens. In this regard, sH4 might be
usefulasabiomarkerfordiagnosisandmonitoringoftheprogression
of RA. On the other hand, sH4 may be potentially utilized to
enhance anti-tumor or anti-viral immunities. Our experiments also
implicate agonist forms of B7-H4 such as B7-H4Ig as a new venue
for the potential treatment of autoimmune diseases.
Supporting Information
Figure S1 Association of sH4 and the levels of CRP in patients
diagnosed with RA. The data are a summary of 68 RA patients
and are analyzed by Spearman’s rank test. y=36.9x295.9,
R
2=0.473, p,0.001.
Found at: doi:10.1371/journal.pmed.1000166.s001 (0.51 MB
TIF)
Figure S2 The levels of sH4 in CIA mice. Mice were immunized
with chicken type II collagen in CFA on day 0 and day 21 and sera
were collected from the mice at the indicated time points and
subjected to ELISA analysis as described in Materials and
Methods. Concentration of serum sH4 was determined by
comparison with purified B7-H4Ig protein. Each point represents
results from a pool of five mice. Data represent two independent
experiments and are expressed as means 6 95% confidence
interval.
Found at: doi:10.1371/journal.pmed.1000166.s002 (0.51 MB
TIF)
Figure S3 Kinetics of sH4 in mouse sera after hydrodynamic
injection of the plasmids. Sera were collected from the mice at the
indicated time points and subjected to ELISA analysis as described
in Materials and Methods. Concentration of serum sH4 was
determined by comparison with purified B7-H4Ig protein. Each
point represents results from a pool of five mice. Data represent
two independent experiments and are expressed as means 6 95%
confidence interval.
Found at: doi:10.1371/journal.pmed.1000166.s003 (0.54 MB
TIF)
Figure S4 Gross appearance of paws of mice after collagen
immunization. Joint swelling of the normal (left) or CIA mice
treated with control vector, B7-H4VC, or B7-H4Ig plasmids on
day 45.
Found at: doi:10.1371/journal.pmed.1000166.s004 (3.11 MB
TIF)
Figure S5 Histology of paws of mice after collagen immuniza-
tion. Hind paws from the normal (left) or CIA mice were treated
with control vector, B7-H4VC, or B7-H4Ig plasmids. On day 35,
tissue sections from the metatarsophalangeal joints of the mice
were prepared and processed by hematoxylin and eosin staining
(magnification, 6100).
Found at: doi:10.1371/journal.pmed.1000166.s005 (2.94 MB
TIF)
Figure S6 Clinical score of mice with CIA treated by control
vector. Mice were immunized with CII in CFA on day 0 and day
21. The clinical scores were recorded based on the standards
described in Methods. Mice in groups of ten were injected with
the indicated plasmids on day 21a n dd a y2 0 .D a t aa r e
representative oftwo independentexperimentsand are expressed
as means 6 95% confidence interval. Statistical analysis was
performed by the repeated ANOVA method (p,0.0001). The
following Tukey-Kramer test showed significant differences at
each points after day 28 between the Flag group and other two
groups (p,0.01).
(p,0.0001). The following Tukey-Kramer test showed significant difference at each points after day 33 (p,0.01). (C) Inhibition of autoantibodies to
collagen by B7-H4Ig. CIA mice in groups of five were treated with indicated plasmids and sera were sampled at day 30 after collagen immunization.
Serum anti-collagen IgG level was determined by specific sandwich ELISA as described in Materials and Methods. The top and bottom of each
rectangular box denote the 75th and 25th percentiles, respectively, with the median shown inside the box. Error bars extending from each box
represent the maximum and minimum. Data represent three independent experiments. The data were analyzed by unpaired Student two-tailed t-
test. (D) Inhibition of T cell proliferation to collagen by B7-H4Ig. CIA mice in groups of five were treated with indicated plasmids as described in (A).
Whole splenocytes from the mice at day 30 after collagen immunization were cultured in the presence of the indicated concentrations of CII for 72 h.
The cultures were pulsed with
3HTdR 18 h before harvest and cpm were counted by a scintillation counter. Each point represents results from three
wells. The data represent three independent experiments and are expressed as means 6 95% confidence interval. (E) Inhibition of IFN-c and IL-17
production responding to collagen by B7-H4Ig. Spleen cells from CIA mice were stimulated as described in (D). Supernatants in the cultures at 72 h
were collected and assessed for IFN-c and IL-17 production by specific sandwich ELISA. Each group represents results from three wells. The data
represent three independent experiments. The top and bottom of each rectangular box denote the 75th and 25th percentiles, respectively, with the
median shown inside the box. Error bars extending from each box represent the maximum and minimum. The data were analyzed by unpaired
Student two-tailed t-test. (F) Suppression of established CIA by treatment with the plasmid containing the gene encoding B7-H4Ig fusion protein.
Mice in groups of 10 were immunized with chicken type II collagen in CFA on day 0 and day 21 and observed daily. When the mice had a clinical
score 2, they were injected with indicated plasmids. The treatment was repeated once 2 wk later. The incidence and clinical score were recorded
based on the standard method described in Materials and Methods. Data are representative of three independent experiments and the data of
clinical scores are expressed as means 6 95% confidence interval. Statistical analysis was performed by the repeated ANOVA method (p,0.0001). The
following Tukey-Kramer test showed significant differences at each point after day 21 (p,0.01).
doi:10.1371/journal.pmed.1000166.g005
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TIF)
Figure S7 Serum titers of autoantibodies. Serum levels of anti-
CII IgG1, IgG2a, and IgG2b from the groups of CIA mice (five
per group) treated with control vector, B7-H4V, B7-H4VC, or B7-
H4Ig were measured by specific sandwich ELISA on day 30 and
expressed as means 6 95% confidence interval. Statistical analysis
was performed by the ANOVA method followed by the Scheffe ´
test.
Found at: doi:10.1371/journal.pmed.1000166.s007 (0.68 MB
TIF)
Figure S8 The proliferation of CD4+ T cells against collagen
type II from CIA mice after exposure to sH4. CD4+T cells were
purified from spleens 30 d after CII immunization and stimulated
in vitro by indicated concentration of CII for 72 h before
harvesting. CIA mice pre-treated with control vector, B7-H4V,
B7-H4VC, or B7-H4Ig prior analysis. The data are presented as
means 6 95% confidence interval.
Found at: doi:10.1371/journal.pmed.1000166.s008 (0.54 MB
TIF)
Figure S9 Effect of neutrophil depletion in the effector phase in
sH4-mediated exacerbation of CIA. CIA mice were treated with
the indicated plasmids at day 21 and day 14. To deplete Gr-1+
cells, mice in groups of ten were injected i.p. with 0.3 mg of anti-
Gr-1 mAb (clone RB6-8C5) or control rat IgG every other day
from day 20, and this treatment was stopped at day 35 after
collagen immunization. The bars are means 6 95% confidence
interval. Data are representative of two independent experiments.
Statistical analysis was performed by repeated ANOVA method
(p,0.0001). The following Tukey-Kramer test showed significant
difference at each points after day 28 between the B7-H4VC+anti-
Gr1 mAb group and CtlV+anti-Gr1 mAb group (p,0.01).
Found at: doi:10.1371/journal.pmed.1000166.s009 (0.58 MB
TIF)
Table S1 Characteristics of patients diagnosed with rheumatoid
arthritis.
Found at: doi:10.1371/journal.pmed.1000166.s010 (0.84 MB
TIF)
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Background. Rheumatoid arthritis (RA) is a chronic disease
caused by abnormal immune responses. In RA, the body’s
own immune system mainly attacks the joints, causing
inflammation in their lining, but can affect other tissues and
organs in the body. About 1% of the population in
developed countries suffer from RA, and it can result in
long-term joint damage, causing significant illness and
disability. Sufferers have chronic pain, loss of function of
the joint, and loss of mobility. The cause of RA is unknown
and there is no known cure. However, neutrophils (an
immune cell important for inflammation) are thought to
contribute to the initiation of RA. Understanding the primary
mechanisms behind the development of RA, and where the
body’s immune system goes wrong, is fundamental not only
to find new treatments for the disease but also to aid
diagnosis to help patients get treatment to help control their
often debilitating symptoms.
Why Was the Study Done? Regulation of the immune
system is necessary to prevent overactivity. Interruptions to
the normal signals that moderate the immune response can
lead to destruction of normal tissues. Previous studies have
shown that the B7 family of proteins, which interact with
CD28 signaling proteins on the surface of immune cells, are
important regulators of the immune response. B7 proteins
have also been found to exist in soluble forms that have
been implicated in the development of rheumatoid diseases,
but their exact role is not well understood. In the current
study, researchers examined a member of the B7 family, B7-
H4, which normally acts as an inhibitor of the immune
response, to find out whether this signaling molecule affects
the immune response and has a role in the development of
RA.
What Did the Researchers Do and Find? The researchers
collected blood from 68 patients with RA and 24 healthy
volunteers, and measured levels of soluble B7-H4, also
known as sH4. They found sH4 in blood from 65% of patients
with RA, compared with only 13% of healthy people. The
levels of sH4 were significantly higher in RA patients
(96.1 ng/ml) compared to healthy people (,5 ng/ml).
Moreover, the highest levels of sH4 were found in patients
with the most severe forms of RA, as measured by a standard
index score that includes general health, the number of
swollen joints, and the amount of inflammation. The
researchers then used a mouse model of RA to explore
how sH4 might contribute to RA. First, they injected mice
with plasmids (circular pieces of DNA that can be used to
transfer genes into organisms) carrying the gene for sH4 and
looked at how overexpression of sH4 affected the
development of arthritis. They also looked at how deleting
the B7-H4 gene in mice affected symptoms. Both
overexpression of sH4 and deletion of B7-H4 caused
inflammation in the mice; symptoms appeared earlier and
were more severe. Furthermore, the effects of sH4 were
shown to be dependent on neutrophils. Finally, the
researchers successfully prevented the development of
disease in mice by using a protein to mimic the normal
signaling by B7-H4, which inhibits the immune response.
What Do these Findings Mean? These findings suggest
that the signaling molecule B7-H4 may be involved in the
development of RA. B7-H4 normally acts as an inhibitor of
the immune response to suppress inflammation, but when
its action is blocked the immune response is no longer
suppressed, and an inappropriate and increased immune
reaction occurs. sH4 is thought to act as a decoy that blocks
binding of B7-H4 to its receptor, thereby preventing an
inhibitory signal to the immune system. Overexpression of
sH4 worsens the symptoms in the mouse model of RA.
Intriguingly, high levels of sH4 were also present in RA
patients and were associated with increased severity of
disease. This study does not establish sH4 as a cause of RA
but implicates sH4 as a cause in the progression of increased
inflammation in this disease. Immune system signaling
molecules have potential as novel targets for treatment of
RA and other autoimmune disorders. However, further
studies are needed to test whether sH4 has a direct role in
the development of RA in humans.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000166.
N MedlinePlus has a topic page on RA providing extensive
information on symptoms and treatment for RA and
access to related clinical trials and medical literature
N The National Rheumatoid Arthritis Society (UK) is a
patient-led charity to provide information, education,
and support for people with RA
N The Arthritis Foundation (US) is a national not-for-profit
organization that supports public health education and
research funding, and provides informational resources
for people with arthritis http://www.arthritis.org/
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